HIV Updates and Insights
Understanding the relationship between social support and physical and mental well-being among jail detainees living with HIV.
Arriola KJ, et al. J Health Psychol. 2015;20(1):3-12.
Jails as an opportunity to increase engagement in HIV care: findings from an observational cross-sectional study.
Avery AK, et al. AIDS Behav. 2013;17(suppl 2):S137-S144.
Beckwith CG, et al. J Acquir Immune Defic Syndr. 2010;55(suppl 1):S49-S55.
The path to implementation of HIV pre-exposure prophylaxis for people involved in criminal justice systems.
Brinkley-Rubinstein L, et al. Curr HIV/AIDS Rep. 2018;15(2):93-95.
Contribution of substance use disorders on HIV treatment outcomes and antiretroviral medication adherence among HIV-infected persons entering jail.
Chitsaz E, et al. AIDS Behav. 2013;17(suppl 2):S118-S127.
Assessing the effect of recent incarceration in prison on HIV care retention and viral suppression in two states.
Costa M, et al. J Urban Health. 2018;95(4):499-507.
Can TasP approaches be implemented in correctional settings? A review of HIV testing and linkage to community HIV treatment programs.
Elkington KS. J Health Care Poor Underserved. 2016;27(2A):71-100.
Understanding the revolving door: individual and structural level predictors of recidivism among individuals with HIV leaving jail.
Fu JJ. AIDS Behav. 2013;17(suppl 2):S145-S155.
The HIV care cascade before, during, and after incarceration: a systematic review and data synthesis.
Iroh PA, et al. Am J Public Health. 2015;105(7):e5-e16.
Practical guidance for nonoccupational postexposure prophylaxis to prevent HIV infection: an editorial review.
Jain S, Mayer KH. AIDS. 2014;28(11):1545-1554.
Transitional care coordination in New York City jails: facilitating linkages to care for people with HIV returning home from Rikers Island.
Jordan AO, et al. AIDS Behav. 2013.17(suppl 2):S212-S219.
Justia U.S. Supreme Court.
Post-release substance abuse outcomes among HIV-infected jail detainees: results from a multisite study.
Krishnan A, et al. AIDS Behav. 2013.17(suppl 2):S171-S180.
The Lancet HIV. 2017;4(11):e475.
Predictors of linkage to HIV care and viral suppression after release from jails and prisons: a retrospective cohort study.
Loeliger KB, et al. Lancet HIV. 2018;5(2):e96-e106.
Evaluation of a prisoner condom access pilot program conducted in one California state prison facility.
Lucas KD, et al. Office of AIDS, Center for Infectious Diseases, California Department of Public Health, 2011.
Opportunities to prevent overdose deaths involving prescription and illicit opioids, 11 states, July 2016–June 2017.
Mattson CL, et al. MMWR Morb Mortal Wkly Rep. 2018;67(34):945-951.
Optimization of human immunodeficiency virus treatment during incarceration: viral suppression at the prison gate.
Mayer JP. JAMA Intern Med. 2014;174(5):721-729.
“Inside these fences is our own little world”: prison-based HIV testing and HIV-related stigma among incarcerated men and women.
Muessig K, et al. AIDS Educ Prev. 2016;28(2):103-116.
Polka E. Public Health Post. September 4, 2018.
Riddell J IV, et al. JAMA. 2018; 319(12):1261-1268.
Rubenstein LS, et al. Lancet. 2016;388(10050):1202-1214.
Rubin R. Lancet. 2016;388(10049):1041-1042.
Spaulding AC, et al. AIDS Behav. 2013;17(suppl 2):S220-S226.
Spaulding AC, et al. AIDS Behav. 2013;17(suppl 2):S100-S107.
Planning for success predicts virus suppressed: results of a non-controlled, observational study of factors associated with viral suppression among HIV-positive persons following jail release.
Spaulding AC, et al. AIDS Behav. 2013;17(suppl 2):S203-S211.
Stein MS, et al. AIDS Behav. 2013;17(suppl 2):S108-S117.
Torriente A, et al. Health Hum Rights. 2016;18(1):157-168.
HIV risk inside U.S. prisons: a systematic review of risk reduction interventions conducted in U.S. prisons.
Valera P, et al. AIDS Care. 2017;29(8):943-952.
Wakeman SE, et al. Med Health R I. 2009;92(7):244-246.
Randomized controlled trial of an intervention to maintain suppression of HIV viremia after prison release: the imPACT trial.
Wohl DA, et al. J Acquir Immune Defic Syndr. 2017;75(1):81-90.
Wurcel AG, et al. Clin Infect Dis. 2015;61(12):1840-1849.
Realities, Challenges, and Opportunities to Improve Care
The PCPs Role in Preventing HIV
What Do You Know About PrEP?
Optimizing Use of Clinical Evidence & Pharmacoeconomic Models in Managed Care
What Do You Know About PrEP?
Got it? Treat it!
The Critical Role of the Community Pharmacist
Bringing Local Communities Together to Eliminate Coinfection Through Knowledge and Partnerships.
Volume 1: Rapid ART Initiation: A New Addition to the HIV-Care Tool Box
Key Issues Impacting OB/GYN Practice
Hot Topics in HBV, HCV, and NASH
Volume II: Expanding Evidence for the Role of Rapid ART Initiation in HIV Practice
Why It Matters in OB/GYN Practice Today
A Treater’s Guide to Optimizing Care in the Aging Patient with Comorbidities
How the Pharmacist Can Make a Difference
HIV Can Be Prevented— Are You Doing Your Part?
Rapid Start ART — A New Model for HIV Care
Understanding the Growing Syndemic — Opioids, HCV, and HIV
A PrEP Primer
The PCP’s Role in HCV Elimination
What the Pharmacist Needs to Know about PrEP
The Rapid ART Standard of Care: From Evidence to Healthcare Equity
Maximizing Your Role to Impact Patient Outcomes
Building Bridges to Reach People Who Inject Drugs With the Goal to Eliminate HCV
Benefits, Barriers, & Best Practices in an Advancing Field
Practical Solutions Across the Spectrum of Care
A PEP/PrEP Training Guide for Pharmacists
A Critical Step Toward HCV Elimination
Considering the Patient, the Provider, and the Science